Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, notes that for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, the principal aim should be to improve their status, allowing them to proceed to transplant and improve their survival. Dr Desai explains how hypomethylating agents (HMAs) and venetoclax make up the backbone of lower-intensity therapy, with additions of other agents such as gilteritinib targeting specific mutations. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
